The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.